INT146343

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.60
First Reported 2002
Last Reported 2010
Negated 1
Speculated 2
Reported most in Body
Documents 17
Total Number 19
Disease Relevance 7.33
Pain Relevance 8.27

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

transport (Slc6a3) plasma membrane (Slc6a3) transmembrane transport (Slc6a3)
Anatomy Link Frequency
nucleus accumbens 2
prefrontal 2
substantia nigra 1
basal ganglia 1
Slc6a3 (Mus musculus)
Pain Link Frequency Relevance Heat
Dopamine 526 100.00 Very High Very High Very High
Ventral tegmentum 35 100.00 Very High Very High Very High
Nucleus accumbens 29 100.00 Very High Very High Very High
cocaine 342 99.84 Very High Very High Very High
addiction 25 98.80 Very High Very High Very High
Eae 77 98.36 Very High Very High Very High
Substantia nigra 13 96.60 Very High Very High Very High
depression 9 96.48 Very High Very High Very High
monoamine 40 96.28 Very High Very High Very High
Migraine 2 95.84 Very High Very High Very High
Disease Link Frequency Relevance Heat
Anxiety Disorder 214 99.72 Very High Very High Very High
Targeted Disruption 177 99.66 Very High Very High Very High
Parkinson's Disease 229 97.96 Very High Very High Very High
Depression 9 96.48 Very High Very High Very High
Congenital Anomalies 12 95.88 Very High Very High Very High
Headache 2 95.84 Very High Very High Very High
Neuralgia 2 95.44 Very High Very High Very High
Attention Deficit Hyperactivity Disorder 75 95.12 Very High Very High Very High
Alcohol Addiction 3 90.08 High High
Stress 28 89.20 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The present study assessed whether FQ is effective in dopamine transporter (DAT) regulation and antiparkinsonism by utilizing in vitro and in vivo assays, respectively.
Spec (whether) Regulation (regulation) of dopamine transporter associated with dopamine
1) Confidence 0.60 Published 2008 Journal Pharmacol. Biochem. Behav. Section Abstract Doc Link 18485464 Disease Relevance 0.34 Pain Relevance 0.50
The present study assessed whether FQ is effective in dopamine transporter (DAT) regulation and antiparkinsonism by utilizing in vitro and in vivo assays, respectively.
Spec (whether) Regulation (regulation) of DAT associated with dopamine
2) Confidence 0.60 Published 2008 Journal Pharmacol. Biochem. Behav. Section Abstract Doc Link 18485464 Disease Relevance 0.34 Pain Relevance 0.49
The importance of the DAT protein in dopaminergic neurotransmission in the basal ganglia suggests extensive involvement of CSTC circuit abnormalities in sequential super-stereotypy in the DAT KD mouse model.
Regulation (importance) of DAT protein in basal ganglia associated with congenital anomalies
3) Confidence 0.51 Published 2008 Journal Current Chemical Genomics Section Body Doc Link PMC2746669 Disease Relevance 1.24 Pain Relevance 0.11
It is commonly believed that DAT-mediated efflux of DA is primarily responsible for the psychostimulant and hyperlocomotor actions of these drugs [38,40,41].
Regulation (responsible) of DAT-mediated associated with dopamine
4) Confidence 0.41 Published 2005 Journal PLoS Biology Section Body Doc Link PMC1181539 Disease Relevance 0 Pain Relevance 0.66
Gene expression, measured using quantitative real-time PCR, revealed a significant approximately 3- to 10-fold up-regulation of dopamine reuptake transporter (DAT) in the ventral tegmental area, nucleus accumbens, and prefrontal cortex and a down-regulation of DAT in the hypothalamus.
Regulation (regulation) of DAT in prefrontal associated with nucleus accumbens, ventral tegmentum and dopamine
5) Confidence 0.38 Published 2010 Journal Endocrinology Section Abstract Doc Link 20685869 Disease Relevance 0.19 Pain Relevance 0.66
Gene expression, measured using quantitative real-time PCR, revealed a significant approximately 3- to 10-fold up-regulation of dopamine reuptake transporter (DAT) in the ventral tegmental area, nucleus accumbens, and prefrontal cortex and a down-regulation of DAT in the hypothalamus.
Regulation (regulation) of DAT in prefrontal associated with nucleus accumbens, ventral tegmentum and dopamine
6) Confidence 0.38 Published 2010 Journal Endocrinology Section Abstract Doc Link 20685869 Disease Relevance 0.20 Pain Relevance 0.68
Tamoxifen at 50 microg reduced the methamphetamine effect on striatal dopamine concentration, dopamine transporter specific binding and prevented the increase in preproenkephalin mRNA levels; in the substantia nigra tamoxifen prevented the decrease of dopamine transporter mRNA levels.
Regulation (effect) of dopamine transporter in substantia nigra associated with dopamine and substantia nigra
7) Confidence 0.34 Published 2007 Journal Biochem. Pharmacol. Section Abstract Doc Link 17825264 Disease Relevance 0.22 Pain Relevance 0.61
It remains a concern that in DAT-CI mice the lack of cocaine response might be due to compensatory changes from the lowered DAT activity.
Regulation (changes) of DAT associated with cocaine
8) Confidence 0.27 Published 2007 Journal BMC Neurosci Section Body Doc Link PMC1914080 Disease Relevance 0.14 Pain Relevance 0.46
Therefore, it is not clear how the modulation of DAT would affect cocaine induced reward and locomotor activity.
Regulation (modulation) of DAT associated with eae and cocaine
9) Confidence 0.24 Published 2007 Journal BMC Neurosci Section Body Doc Link PMC1914080 Disease Relevance 0.40 Pain Relevance 0.80
In DAT-CI mice, the mutated DAT is over 50-fold less sensitive to cocaine inhibition but has lower uptake activity.
Regulation (sensitive) of DAT associated with cocaine
10) Confidence 0.24 Published 2007 Journal BMC Neurosci Section Body Doc Link PMC1914080 Disease Relevance 0 Pain Relevance 0.58
Since this VNTR is not in the coding region of the DAT gene, it does not affect the protein sequence of the dopamine transporter, but may affect the translational efficiency and thus the amount of protein expressed.
Neg (not) Regulation (affect) of dopamine transporter associated with dopamine
11) Confidence 0.23 Published 2002 Journal BMC Neurosci Section Body Doc Link PMC130047 Disease Relevance 0.72 Pain Relevance 0.32
Differences in DAT regulation may contribute to defining the pattern of DA time signaling and functional specialization in the dSt and vSt (Wickens et al., 2003).
Regulation (regulation) of DAT
12) Confidence 0.19 Published 2010 Journal Frontiers in Neuroanatomy Section Body Doc Link PMC2978035 Disease Relevance 0.25 Pain Relevance 0.10
DAT-KO mice lack a key target of AMPH, the DA transporter [21]; thus, it is likely that AMPH exerts a calming effect via serotonergic mechanisms [23], [24].
Regulation (target) of DA transporter associated with targeted disruption and dopamine
13) Confidence 0.18 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2668764 Disease Relevance 0.95 Pain Relevance 0.08
DAT-KO mice lack a key target of AMPH, the DA transporter [21], and thus the drug exerts a calming effect via serotonergic mechanisms [23], [24].
Regulation (target) of DA transporter associated with targeted disruption and dopamine
14) Confidence 0.18 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2668764 Disease Relevance 0.57 Pain Relevance 0.12
Given that DAT activity depends on its glycosylation status and membrane expression, we then explored a possible relationship between DAT glycosylation and function and the differential vulnerability of DA-cells (Afonso-Oramas et al., 2009).
Regulation (depends) of DAT
15) Confidence 0.16 Published 2010 Journal Frontiers in Neuroanatomy Section Body Doc Link PMC2978035 Disease Relevance 0.21 Pain Relevance 0.09
Gene expression, measured using quantitative real-time PCR, revealed a significant approximately 3- to 10-fold up-regulation of dopamine reuptake transporter (DAT) in the ventral tegmental area, nucleus accumbens, and prefrontal cortex and a down-regulation of DAT in the hypothalamus.
Regulation (regulation) of DAT in nucleus accumbens associated with nucleus accumbens, ventral tegmentum and dopamine
16) Confidence 0.13 Published 2010 Journal Endocrinology Section Abstract Doc Link 20685869 Disease Relevance 0.20 Pain Relevance 0.68
Gene expression, measured using quantitative real-time PCR, revealed a significant approximately 3- to 10-fold up-regulation of dopamine reuptake transporter (DAT) in the ventral tegmental area, nucleus accumbens, and prefrontal cortex and a down-regulation of DAT in the hypothalamus.
Regulation (regulation) of DAT in nucleus accumbens associated with nucleus accumbens, ventral tegmentum and dopamine
17) Confidence 0.13 Published 2010 Journal Endocrinology Section Abstract Doc Link 20685869 Disease Relevance 0.19 Pain Relevance 0.66
For example, targeting the DAT should be useful in treating addiction to any Class III drug.
Regulation (targeting) of DAT associated with addiction
18) Confidence 0.09 Published 2006 Journal PLoS Medicine Section Body Doc Link PMC1635740 Disease Relevance 0.20 Pain Relevance 0.68
Changes in TH and DAT proteins were next quantified by WB in saline and MPTP mice fed with the control or HCT1026 diet (Figure 3I and 3J).
Regulation (Changes) of DAT associated with parkinson's disease
19) Confidence 0.07 Published 2010 Journal J Neuroinflammation Section Body Doc Link PMC3000390 Disease Relevance 0.96 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox